Factors related to risk of recurrence and recurrence free survival in ameloblastoma of the Jaws: A single centre retrospective analysis
- PMID: 39739058
- DOI: 10.1007/s10006-024-01321-3
Factors related to risk of recurrence and recurrence free survival in ameloblastoma of the Jaws: A single centre retrospective analysis
Abstract
Purpose: Ameloblastoma is a benign tumor originating from odontogenic epithelium with a global incidence of about 0.5 cases per million persons per year. The overall recurrence rate of ameloblastomas range from 55% -90%. In this retrospective study we have analyzed the factors associated with recurrence and recurrence free survival in ameloblastoma of the jaws.
Methods: Retrospective chart review of 10 years was done from records directory. All demographic data, data on diagnostic modalities, clinical presentations, radiology, management and histology were taken into consideration. Kaplan Meir estimator was used to evaluate recurrence rate and Cox regression analysis (univariate and multivariate) was used to evaluate the odds ratio to find out the possible factors influencing risk of recurrence and influence recurrence free survival. ROC curve (Receiver Operating Characteristic) was used to find out the optimal cut off point for size of the lesion in predicting recurrence. A p value of < 0.05 was considered statistically significant at 95% confidence interval.
Results: A total of 75 patients had recurrence with a median follow up of 65 months. The overall 5 year RFS was 19.5%. Conventional ameloblastomas, cortical/ soft tissue invasion, conservative treatment and tumor size ≥ 4 cm were independent predictors of recurrence.
Conclusion: Aggressive treatment is preferred for conventional ameloblastomas ≥ 4 cm with cortical/ soft tissue invasion.
Keywords: Ameloblastoma; Jaws; Recurrence; Recurrence free survival.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical Approval: Obtained (Dean/2022/EC/3450). Consent to participate: Informed and written consent was obtained from all patients during initial treatment. Consent to Publish: All authors give full consent to publish. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Recurrence factors in pediatric ameloblastoma: Clinical features and a new classification system.Head Neck. 2019 Oct;41(10):3491-3498. doi: 10.1002/hed.25867. Epub 2019 Jul 19. Head Neck. 2019. PMID: 31322781
-
COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma.Pathol Res Pract. 2018 Jun;214(6):907-913. doi: 10.1016/j.prp.2018.03.014. Epub 2018 Mar 15. Pathol Res Pract. 2018. PMID: 29559247
-
Unicystic ameloblastoma: A retrospective study on recurrent factors from a single institute database.Oral Dis. 2024 Apr;30(3):1475-1482. doi: 10.1111/odi.14477. Epub 2023 Jan 4. Oral Dis. 2024. PMID: 36564985
-
Ameloblastoma: biological profile of 3677 cases.Eur J Cancer B Oral Oncol. 1995 Mar;31B(2):86-99. doi: 10.1016/0964-1955(94)00037-5. Eur J Cancer B Oral Oncol. 1995. PMID: 7633291 Review.
-
Surgical management of conventional ameloblastoma: a retrospective cohort study over the past 21 years.Oral Maxillofac Surg. 2024 Nov 4;29(1):4. doi: 10.1007/s10006-024-01296-1. Oral Maxillofac Surg. 2024. PMID: 39495234 Review.
Cited by
-
A multi-center cross-sectional investigation of BRAF V600E mutation in Ameloblastoma.PeerJ. 2025 Apr 3;13:e19137. doi: 10.7717/peerj.19137. eCollection 2025. PeerJ. 2025. PMID: 40191760 Free PMC article.
References
-
- Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO (2015) Ameloblastoma: current etiopathological concepts and management. Oral Dis 24(3):307–316. https://doi.org/10.1111/odi.12646 - DOI
-
- Shi HA, Ng CWB, Kwa CT, Sim QXC (2021) Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies. Surgeon 19(4):238–243. https://doi.org/10.1016/j.surge.2020.06.009 - DOI - PubMed
-
- Soluk-Tekkesin M, Wright JM (2022) The World Health Organization Classification of Odontogenic Lesions: A Summary of the Changes of the 2022 (5th) Edition. Turk Patoloji Derg. 38(2):168–184. https://doi.org/10.5146/tjpath.2022.01573 - DOI - PubMed - PMC
-
- Ghai S (2022) Ameloblastoma: An Updated Narrative Review of an Enigmatic Tumor. Cureus 14(8):e27734. https://doi.org/10.7759/cureus.27734 - DOI - PubMed - PMC
-
- Yang R, Liu Z, Gokavarapu S, Peng C, Ji T, Cao W (2017) Recurrence and cancerization of ameloblastoma: multivariate analysis of 87 recurrent craniofacial ameloblastoma to assess risk factors associated with early recurrence and secondary ameloblastic carcinoma. Chin J Cancer Res 29(3):189–195. https://doi.org/10.21147/j.issn.1000-9604.2017.03.04 - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources